The US pharmacy giant CVS Health is to contract with global biosimilars player Sandoz to commercialize and bring to market its Hyrimoz (adalimumab-adaz) biosimilar to Humira as the first product imagined by the launch of its wholly owned US biosimilars subsidiary called Cordavis.
According to CVS, the Cordavis products “will be US Food and Drug Administration approved, high quality, and easy for patients to use and will help ensure